CDK1 and plasma cell myeloma: The CDK1/4/9 inhibitor P276-00 showed promising in vitro and in vivo results in AML [109], myeloma [110], and mantle cell lymphoma [111] but only achieved SD in two out of 13 R/R mantle cell lymphoma patients in a phase II clinical trial [112].